希瑪眼科(03309.HK)成立合資公司及向藥監局申請OK鏡在中國註冊
格隆匯8月26日丨 希瑪眼科(03309.HK)公吿，希瑪眼科欣然公佈於今天正式簽署合作協定，將於香港成立合資公司，開展設計、生產和分銷以角膜塑形鏡Orthokeratology Lens("OK鏡")為主的兒童近視防控鏡片業務。
合資公司初步的註冊資本為港幣1,500萬，希瑪佔股55%，合資夥伴佔股45%，雙方按比例出資。合資公司成立後，會盡快啟動OK鏡產品在國家藥品監督管理局("藥監局")的註冊申請，包括在香港和內地就OK鏡產品進行臨牀測試和建立生產基地。
合資夥伴Driemlens Investment Limited，是香港歷史悠久的OK鏡設計、生產和研發企業E&EOpticsLimited(易安易光學)的控股公司。E&EOptics是亞洲首批、香港第一間公司將OK鏡產品成功引入亞洲的企業；也是首批取得國家食品藥品監督管理總局(藥監局的前身)於內地合法出售OK鏡產品的企業。E&EOptics的豐富經驗和優秀的產品品質一直受使用者、市場和業界的廣泛認可和尊重。
E&EOptics目前已發展成一間全面設計及生產各種高透氧硬性阻形眼鏡的公司，除OK鏡以外，還有一般的隱形眼鏡、圓錐角膜用鏡片、多焦點老花鏡片、角膜手術後視力矯正鏡片和大直徑鞏膜鏡片等。E&EOptics現時在香港生產的鏡片，除供應香港及澳門市場外，E&EOptics的產品亦出口到亞非多國，如日本、新加坡、馬來西亞、斯里蘭卡、斐濟、杜拜、埃及、澳大利亞等。
據2020年國家衞健委疾控局近視調查，中國全國兒童青少年2020年總體近視率為52.7%，近視防控已上升至國家戰略。OK鏡是世界衞生組織推薦的防控近視方法之一。根據國家衞健委《近視防控指南》，臨牀試驗發現長期配戴OK鏡可延緩青少年眼軸長度進展約0.19毫米╱年，明顯能減慢青少年近視加深的速度。
根據中國醫療器械行業協會眼科及視光學分會資料顯示，2018年我國OK鏡的使用量為64萬副，行業滲透率只有1%左右，而在發達國家和地區，尤其是生理結構與中國較為類似的東亞地區，塑形鏡的平均滲透率都在5%以上。董事相信OK鏡在中國的市場滲透率會持續上升。
希瑪眼科作為中國最大的港資眼科醫療集團，成立合資公司標誌希瑪進一步擴展至眼科產業鏈上游產品包括OK鏡在內的研發、製造、及分銷等業務，配合國家加強青少年近視防控的政策。且與E&EOptics的合作，希瑪也期望可同時推動香港和大灣區在近視防控產品的研發和產業發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
